Annals of Surgical Oncology

, Volume 25, Issue 8, pp 2434–2440 | Cite as

Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety

  • Naoya Yoshida
  • Yoshifumi Baba
  • Yuji Miyamoto
  • Masaaki Iwatsuki
  • Yukiharu Hiyoshi
  • Takatsugu Ishimoto
  • Yu Imamura
  • Masayuki Watanabe
  • Hideo Baba
Gastrointestinal Oncology



The incidence of venous thromboembolism (VTE) after esophagectomy is higher than in other gastroenterological cancer surgery. Although the effectiveness and safety of thromboprophylaxis using enoxaparin have been established in orthopedic, abdominal, and pelvic surgeries, no studies regarding esophagectomy are available.


A prospective observational study was conducted to elucidate the usefulness of enoxaparin for VTE prophylaxis after esophagectomy. The study enrolled 30 patients who underwent elective esophagectomy for esophageal cancer between April 2015 and October 2016. During postoperative days 2–11, the patients received a subcutaneous injection of enoxaparin (2000 IU) twice daily. The primary end point for the study was the incidence of postoperative VTE. In addition, the incidence of all enoxaparin treatment- and operation-related adverse events was investigated. The study identified VTE by VTE protocol-enhanced computed tomography, performed routinely during and after enoxaparin treatment.


One pulmonary embolism (PE) (3.3%) and two deep vein thromboses (DVTs) (6.7%) were observed during enoxaparin treatment. In addition, one PE (3.6%) and four DVTs (14.3%) (one patient experienced both) were observed after treatment. All VTEs were asymptomatic. Regarding enoxaparin-related adverse events, four minor bleeds occurred but did not require discontinuation of enoxaparin. The incidence of postoperative morbidity was acceptable. In blood tests related to coagulation, no significant differences were observed between patients with and without VTE.


The authors believe that thromboprophylaxis using enoxaparin is safe and can prevent VTE after esophagectomy. However, its effectiveness is limited to the period of treatment, so additional prophylaxis may be recommended.



Drs. Naoya Yoshida and Takatsugu Ishimoto have course affiliation with Chugai Pharmaceutical Co., Ltd and Yakuruto Honsya Co., Ltd. Hideo Baba and the other co-authors (Y.B., Y.M., M.I., Y.H., Y.I., M.W.) have no conflicts of interest or financial ties to disclose.

Supplementary material

10434_2018_6552_MOESM1_ESM.doc (37 kb)
Supplementary material 1 (DOC 37 kb)


  1. 1.
    Bellini G, Teng A, Kotecha N, et al. The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery. J Surg Res. 2016;205:279–85.CrossRefPubMedGoogle Scholar
  2. 2.
    De Martino RR, Goodney PP, Spangler EL, et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg. 2012;55:1035–40.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hammond J, Kozma C, Hart JC, Nigam S, Daskiran M, Paris A, Mackowiak JI. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol. 2011;18:3240–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Martin JT, Mahan AL, Ferraris VA, Saha SP, Mullett TW, Zwischenberger JB, Tzeng CW. Identifying esophagectomy patients at risk for predischarge versus postdischarge venous thromboembolism. Ann Thorac Surg. 2015;100:932–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Mantziari S, Gronnier C, Pasquer A, et al. Incidence and risk factors related to symptomatic venous thromboembolic events after esophagectomy for cancer. Ann Thorac Surg. 2016;102:979–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Kato F, Takeuchi H, Matsuda S, Kawakubo H, Omori T, Kitagawa Y. Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study. Surg Today. 2016;46:445–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452–66.CrossRefPubMedGoogle Scholar
  8. 8.
    Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015;33:654–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227–77. Erratum in Chest. 2012;141:1369.Google Scholar
  10. 10.
    JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75:1258–81.CrossRefGoogle Scholar
  11. 11.
    Song JQ, Xuan LZ, Wu W, Huang JF, Zhong M. Low-molecular-weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial. J Thorac Dis. 2015;7:1158–64.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Parry K, Sadeghi AH, van der Horst S, Westerink J, Ruurda JP, van Hillegersberg R. Intermittent pneumatic compression in combination with low-molecular-weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. J Surg Oncol. 2017;115:181–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Cimminiello C, Prandoni P, Agnelli G, et al. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med. 2017;12:1291–305.CrossRefPubMedGoogle Scholar
  14. 14.
    Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, Okamoto A. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J Obstet Gynaecol Res. 2015;41:1440–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Hashimoto D, Nakagawa S, Umezaki N, et al. Efficacy and safety of postoperative anticoagulation prophylaxis with enoxaparin in patients undergoing pancreatic surgery: a prospective trial and literature review. Pancreatology. 2017;17:464–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Dranitsaris G, Jelincic V, Choe Y. Meta-regression analysis to indirectly compare prophylaxis with dalteparin or enoxaparin in patients at high risk for venous thromboembolic events. Clin Appl Thromb Hemost. 2012;18:233–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res. 2010;125:e65–70.CrossRefPubMedGoogle Scholar
  18. 18.
    Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer. TNM Classification of Malignant Tumours. 7th ed. Wiley-Blackwell: Chichester; 2010Google Scholar
  19. 19.
    Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012, edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Yoshida N, Baba Y, Shigaki H, et al. Preoperative nutritional assessment by controlling nutritional status (CONUT) is useful to estimate postoperative morbidity after esophagectomy for esophageal cancer. World J Surg. 2016;40:1910–17.CrossRefPubMedGoogle Scholar
  21. 21.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chung WS, Lin CL, Kao CH. Diabetes increases the risk of deep-vein thrombosis and pulmonary embolism: a population-based cohort study. Thromb Haemost. 2015;114:812–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Wattanakit K, Lutsey PL, Bell EJ, et al. Association between cardiovascular disease risk factors and occurrence of venous thromboembolism: a time-dependent analysis. Thromb Haemost. 2012;108:508–15.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hansen-Krone IJ, Brækkan SK, Enga KF, Wilsgaard T, Hansen JB. Alcohol consumption, types of alcoholic beverages, and risk of venous thromboembolism: the Tromsø Study. Thromb Haemost. 2011;106:272–8.CrossRefPubMedGoogle Scholar
  25. 25.
    van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMedGoogle Scholar
  26. 26.
    Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMedGoogle Scholar
  28. 28.
    Bosch DJ, Van Dalfsen QA, Mul VE, Hospers GA, Plukker JT. Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy. Am J Surg. 2014;208:215–21.CrossRefPubMedGoogle Scholar
  29. 29.
    Sabra MJ, Smotherman C, Kraemer DF, Nussbaum MS, Tepas JJ Rd, Awad ZT. The effects of neoadjuvant therapy on morbidity and mortality of esophagectomy for esophageal cancer: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) 2005–2012. J Surg Oncol. 2017;115:296–300.Google Scholar
  30. 30.
    Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol. 2011;37:1072–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Agzarian J, Linkins LA, Schneider L, et al. Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: a comprehensive Canadian Delphi survey. J Thorac Dis. 2017;9:80–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Byrne M, Reynolds JV, O’Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. Br J Cancer. 2010;102:73–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Shah SP, Xu T, Hooker CM, et al. Why are patients being readmitted after surgery for esophageal cancer? J Thorac Cardiovasc Surg. 2015;149:1384–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422–30.CrossRefPubMedGoogle Scholar
  35. 35.
    Cha SI, Lee SY, Kim CH, et al. Venous thromboembolism in Korean patients undergoing major orthopedic surgery: a prospective observational study using computed tomographic (CT) pulmonary angiography and indirect CT venography. J Korean Med Sci. 2010;25:28–34.CrossRefPubMedGoogle Scholar
  36. 36.
    Schramm D, Bach AG, Meyer HJ, Surov A. Thrombotic events as incidental finding on computed tomography in intensive care unit patients. Thromb Res. 2016;141:171–4.CrossRefPubMedGoogle Scholar
  37. 37.
    van Es N, van der Hulle T, Büller HR, Klok FA, Huisman MV, Galipienzo J, Di Nisio M. Is stand-alone D-dimer testing safe to rule out acute pulmonary embolism? J Thromb Haemost. 2017;15:323–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide Web-based database. Ann Surg. 2014;260:259–66.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Naoya Yoshida
    • 1
    • 2
  • Yoshifumi Baba
    • 2
  • Yuji Miyamoto
    • 2
  • Masaaki Iwatsuki
    • 2
  • Yukiharu Hiyoshi
    • 2
  • Takatsugu Ishimoto
    • 1
    • 2
  • Yu Imamura
    • 2
    • 3
  • Masayuki Watanabe
    • 2
    • 3
  • Hideo Baba
    • 1
    • 2
  1. 1.Division of Translational Research and Advanced Treatment Against Gastrointestinal CancerKumamoto University HospitalKumamotoJapan
  2. 2.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  3. 3.Department of Gastroenterological SurgeryCancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations